AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01137188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low calorie diet
Description: Low calorie diet containing 800-1000 kcal/day
Study NCT02486601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel : 150 mg/m2 D1 every 2 weeks
Study NCT02486601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: Leucovorin: 400 mg/m2 D1 every 2 weeks Oxaliplatin: 85 mg/m2 D1 every 2 weeks Fluorouracil (5-FU) infusion: 2400mg/m2 48h infusion every 2 weeks
Study NCT00541918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diprivan (propofol, Astra Zeneca)
Description: Total intravenous anesthesia with propofol
Study NCT00541918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevorane (sevoflurane, Abbott)
Description: inhaled anesthesia with sevoflurane
Study NCT00085202 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously
Study NCT02754687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11βmethyl nortestosterone dodecylcarbonate
Description: Escalating doses of 100, 200, 400, and 800 mg 11β-MNTDC
Study NCT00849511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melatonin
Description: Circadin (melatonin) 2 mg ret. TAB vesp. for 8 weeks
Study NCT00085202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT02360150 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: second propeller arm scanner
Description: The experimental procedure is to conduct a second helical scanner strictly centered on the heart, 10 minutes after the first helix without inject contrast medium, to assess late enhancement.
Study NCT04858061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Cue Exposure Therapy
Description: Exposure to alcohol-related cues within virtual environments
Study NCT04858061 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-as-usual
Description: Pharmacotherapy and psychotherapy
Study NCT00626821 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenSura
Description: Real life assessment of SenSura
Study NCT02448537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM01183
Study NCT02448537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Study NCT02448537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT01758731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib PO (25, 50, 100 or 200 mg bid) in combination with RT and C225. BID, beginning three days prior to first C225 infusion and discontinued after RT completed.
Study NCT01758731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Pre-RT cetuximab (C225), 400 mg/m²IV and weekly C225, 250 mg/m2 IV in during RT.
Study NCT01758731 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: RT to a total dose of 69.3 Gy (primary tumor and involved lymph nodes) in 33 fractions over 6 and 1/2 weeks
Study NCT03953495 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Better Together
Description: The Better Together Intervention consists of a 7 self-paced online relationship education modules. Following an introductory and overview module couples will complete each of the following together on their web-connected device (computer, ipad, phone). Each module includes didactic material, demonstration vignettes, and guided discussions or skills building exercises. Module 1 focuses on identifying individual and relationship strengths; Module 2 focuses on destructive communication patterns, Module 3 focuses on positive communication skills; Module 4 teaches a problem-solving technique; Module 5 focuses on stress and coping; Module 6 focuses on relationship expectations and commitment, and Module 7 provides a summary of the program. Each module takes approximately 30 minutes to an hour to complete. Metrics will be assessed at baseline, post-intervention, and at a 3 month follow up.
Study NCT02348801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss and Exercise
Description: Group behavior therapy sessions designed to acquire positive weight-control skills and attitudes, and practice weight-maintenance skills. A balanced diet will be prescribed to provide a deficit of 500-750 kcal/day from daily energy requirement.~Exercise sessions of \~90 min duration 15 min warm-up of flexibility exercise, followed by \~30 min of aerobic exercise, and, after a brief rest period, \~30 min of resistance training, and finally \~15 min balance exercise) conducted three times weekly supervised at our exercise facility for first six months, and regular exercises continued at community-fitness centers and at home for the following six months.
Study NCT02348801 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy lifestyle
Description: Diabetes support and education
Study NCT01340027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron
Description: oral
Study NCT01340027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: oral
Study NCT01340027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin succinate
Description: oral
Study NCT01340027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate
Description: oral
Study NCT01340027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT04191369 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Esophagogastroduodenoscopy
Description: Esophogagastroduodenoscopy for the evaluation of esophageal varices, gastric varices and hypertensive gastropathy. Portal pressure gradient will be evaluated via interventional radiology as gold standard.
Study NCT04191369 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound
Description: Endoscopic ultrasound evaluation for the presence of esophageal varices, peri and para-esophageal collateral veins, gastric varices, portal hypertensive gastropathy, azygos vein diameter, blood flow and BFVI.~Portal pressure gradient will be evaluated via interventional radiology as gold standard.
Study NCT01728818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m² d1,8,15 q4weeks
Study NCT01728818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: 40mg flat dose, po, once daily
Study NCT01728818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m², d1,8,15 q4weeks
Study NCT00085202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00085202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: Given IV
Study NCT00085202 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Patients undergo autologous stem cell transplantation
Study NCT00085202 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo craniospinal radiotherapy once daily 5 days a week for 6 weeks.
Study NCT01860469 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vancomycin-soaked mesh
Study NCT01860469 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: plain mesh
Study NCT02571270 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined aerobic and resistance physical training program
Study NCT00628901 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine Fibroid Embolization (UFE)
Description: Uterine Fibroid Embolization is used in treating Uterine Fibroids. The procedure involves injecting embolization particles into the fibroid via the uterine artery which causes the fibroid to shrink or subside. Patients are usually released from the hospital the day after the procedure.
Study NCT00628901 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uterine Fibroid Embolization (UFE)
Description: Uterine Fibroid Embolization is used in treating Uterine Fibroids. The procedure involves injecting embolization particles into the fibroid via the uterine artery which causes the fibroid to shrink or subside. Patients are usually released from the hospital the day after the procedure.
Study NCT00628901 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contour SE™ Microspheres
Description: Polyvinyl alcohol Microsphere embolization devices intended to provide targeted vascular occlusion or reduction of blood flow upon selective placement and are currently marketed for use in hypervascular tumors, including leiomyoma uteri and arteriovenous malformations
Study NCT00628901 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Embosphere® Microspheres
Description: Biocompatible, hydrophilic, nonresorbable, microspheres used in the embolization of arteriovenous malformations, hypervascular tumors, and symptomatic uterine fibroids.
Study NCT00894673 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heparin sodium Hipolabor
Description: Heparin sodium Hipolabor 5.000 UI/mL
Study NCT00894673 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Heparin sodium APP
Description: Heparin sodium APP 5.000 USP
Study NCT02889133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron-dextran
Description: Approved for clinical use: 1-gram dose IV - diluted in 500 mL, one pint normal saline.
Study NCT02889133 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iron-dextran
Description: Approved for clinical use: 1-gram dose IV - diluted in 500 mL, one pint normal saline.
Study NCT02889133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Salt water IV - 500 mL, one pint normal saline.
Study NCT02889133 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Salt water IV - 500 mL, one pint normal saline.
Study NCT02889133 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Donation
Description: Standard process of collecting and storing blood and blood components (approximately 450 mL, or a pint of blood). Following donation, the blood will be leukoreduced, packed, and stored in AS-3 solution.
Study NCT02889133 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood Donation
Description: Standard process of collecting and storing blood and blood components (approximately 450 mL, or a pint of blood). Following donation, the blood will be leukoreduced, packed, and stored in AS-3 solution.
Study NCT02889133 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 24-hour PTR
Description: The way the FDA determines how good blood is for transfusion is called a radioactive 51-Chromium 24-hour post-transfusion red cell recovery study. The purpose is to measure how many of the transfused red cells are still in circulation (being pumped by the heart through blood vessels) 24 hours after transfusion. In order to measure the percent of red cells that are still in circulation, a small amount of the donated blood will be radioactively labeled. This will be infused in one arm and then blood will be collected from the other arm at different time points to measure how much of the transfused red cells are still in circulation.
Study NCT02889133 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: 24-hour PTR
Description: The way the FDA determines how good blood is for transfusion is called a radioactive 51-Chromium 24-hour post-transfusion red cell recovery study. The purpose is to measure how many of the transfused red cells are still in circulation (being pumped by the heart through blood vessels) 24 hours after transfusion. In order to measure the percent of red cells that are still in circulation, a small amount of the donated blood will be radioactively labeled. This will be infused in one arm and then blood will be collected from the other arm at different time points to measure how much of the transfused red cells are still in circulation.
Study NCT02304276 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 18F-Fluoride PET-CT
Description: Injection of 18F-Fluoride with target activity 125MBq giving an anticipated radiation exposure of 3mSv CT scanning protocol giving an anticipated radiation exposure of 13mSv
Study NCT02304276 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-Fluoride PET-CT
Description: Injection of 18F-Fluoride with target activity 125MBq giving an anticipated radiation exposure of 3mSv CT scanning protocol giving an anticipated radiation exposure of 13mSv
Study NCT02304276 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT calcium score of aortic valve
Description: CT associated with an anticipated radiation exposure of 3mSv (Cohorts 2 and 3 only)
Study NCT02265614 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PGS
Study NCT01060553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Description: This project was initially designed as a randomized trial with one group receiving treatment and the other wait list control, with delayed treatment. Due to extremely high dropout and cancellations and failure to return for post assessment, a midpoint assessment was added. Analysis was done on pre and post measures of all subjects who completed at least the midpoint assessment. Due to the very small number of subjects in the wait list control, the ones who completed 6 or 12 weeks of acupuncture after the wait list were combined with the few who completed the initial acupuncture for a pre-post single group analysis. for those who completed both the 6 and 12 week measures, the latest one was selected for analysis
Study NCT01546259 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Water colonoscopy
Description: Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
Study NCT03991117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resistance exercise
Description: unilateral knee extensions until fatigue with varying load and speeds of contraction
Study NCT02246335 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cemented total hip arthroplasty
Study NCT02246335 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cemented hemiarthroplasty
Study NCT04806594 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Papix acne scar
Description: PapiX acne scar, class IIa medical device, gel for acne scar. to be applied 2 times per day during the 8 weeks of study duration
Study NCT02037438 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONV care for the diagnosis and treatment of sleep disorders
Description: The Conventional (CONV) intervention utilized standard-of-care diagnostic and treatment procedures for new patients with sleep disorders at the Stanford Sleep Medicine Center
Study NCT02037438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PCCM for the diagnosis and treatment of sleep disorders
Description: The Patient-Centered Outcomes and Coordinated Care Management (PCCM) intervention implemented new methodologies for the diagnosis and treatment of sleep disorders. It also incorporates the utilization of a web-based interactive portal that provides specific and relevant information and resources for patients, health care providers, and allied health professionals. The portal was designed to facilitate informed health care decisions among patients and health care providers through improved access to medical data and enhanced communications.
Study NCT02255032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 mg CLS-TA
Description: 40 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)
Study NCT02255032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.8 mg CLS-TA
Description: 8 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)
Study NCT03871088 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Description: 12-week double-blind, randomized controlled trial
Study NCT03871088 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids
Description: 12-week double-blind, randomized controlled trial
Study NCT02149446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgisis (C-SLRA-ECH60) made by COOK Medical
Description: Surgisis is extracellular matrix collagen made of the submucosal layer of pigs intestines. Surgisis is gradually remodeled, leaving behind organized tissue
Study NCT03601312 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure and Response Prevention
Description: Exposure and response prevention is an evidence-based behavioral treatment that primarily focuses on exposures, in which the child faces OCD-related fears in a methodical manner and acquires more adaptive coping strategies.
Study NCT03601312 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OC-Go
Description: OC-Go is a HIPAA-compliant web-based clinician portal and patient-side mobile application that allows clinicians to create and push tailored treatment assignments to patients on their mobile devices. Individuals receiving this intervention will receive exposure and response prevention with OC-Go.
Study NCT03220295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Dose of VU319
Description: Single dose of VU319
Study NCT03220295 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single Dose Placebo
Description: Single dose of placebo
Study NCT03051997 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver Contingency Management + Usual Drug Court Treatment
Description: In addition to receiving JDC treatment as usual described below, caregiver participants will receive prize draws for engaging in activities consistent with their adolescents' successful completion of the JDC program during the time the youth is actively involved in JDC and substance abuse treatment. Specific activities that may be reinforced include: attendance at drug court hearings; accompanying the youth to probation meetings; participating in home visits; attendance at the youth's drug treatment sessions; attendance at mental health provider meetings; attending groups for parents of youth with substance abuse issues; and completing other verifiable treatment-related activities. All activities will meet the goals of (directly or indirectly) enhancing caregiver participation in the JDC and/or treatment process. Caregivers will receive escalating chances for tangible reinforcers each week for completing up to 3 of the activities agreed upon by the caregiver and the therapist.
Study NCT03051997 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Drug Court Treatment
Description: Standard outpatient substance abuse treatment services that a young person would receive while participating in JDC.
Study NCT01650493 — intervention group
Intervention type: DEVICE
Intervention: Clinpro 5000
Description: Dentrifice containing 950ppm fluoride
Study NCT03220295 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fed State
Description: drug is given 30 minutes after a high fat breakfast
Study NCT01650493 — intervention group
Intervention type: DEVICE
Intervention: MI Paste Plus
Description: Dentrifice containing 950ppm fluoride
Study NCT01650493 — intervention group
Intervention type: DEVICE
Intervention: Tom's of Maine
Description: Dentrifice that is fluoride free
Study NCT03220295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fed State
Description: drug is given 30 minutes after a high fat breakfast
Study NCT03220295 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fasted State
Description: drug is given after an overnight fast
Study NCT03220295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasted State
Description: drug is given after an overnight fast
Study NCT03484078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration Platform
Description: The vibration platform will emit a mild vibration when the participant stands on it 10 minutes per day for 6 months.
Study NCT03484078 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Platform
Description: The placebo platform will not vibrate when the participant stands on it 10 minutes per day for 6 months.
Study NCT03535350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Dose response of Ibrutinib. Level 1 starting dose is 420mg daily. Level 2 starting dose is 560mg daily. Level -1 starting dose is 280mg daily.~November 2020:~420 mg of ibrutinib plus temozolomide and radiation was found to be safe - up to 36 participants can betreated at the expansion cohort in both arm 1 and arm 2.
Study NCT03220295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Escalation of VU319
Description: dose levels of the cohorts will be increased step wise
Study NCT03535350 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 2Gy x 30minutes for 6 weeks.